Literature DB >> 22705107

Microbicides: still a long road to success.

Christophe Vanpouille1, Anush Arakelyan, Leonid Margolis.   

Abstract

The development of efficient microbicides, the topically applied compounds that protect uninfected individuals from acquiring HIV-1, is a promising strategy to contain HIV-1 epidemics. Such microbicides should of course possess anti-HIV-1 activity, but they should also act against other genital pathogens, which facilitate HIV-1 transmission. The new trend in microbicide strategy is to use drugs currently used in HIV-1 therapy. The success of this strategy is mixed so far and is impaired by our limited knowledge of the basic mechanisms of HIV-1 transmission as well as by the inadequacy of the systems in which microbicides are tested in preclinical studies. Published by Elsevier Ltd.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22705107      PMCID： PMC3756685          DOI： 10.1016/j.tim.2012.05.005

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  85 in total

1.  Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety.

Authors:  Anna-Barbara Moscicki; Rupert Kaul; Yifei Ma; Mark E Scott; Ibrahim I Daud; Elizabeth A Bukusi; Stephen Shiboski; Anuradha Rebbapragada; Sanja Huibner; Craig R Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

2.  Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.

Authors:  Graciela Andrei; Andrea Lisco; Christophe Vanpouille; Andrea Introini; Emanuela Balestra; Joost van den Oord; Tomas Cihlar; Carlo-Federico Perno; Robert Snoeck; Leonid Margolis; Jan Balzarini
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

3.  Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network.

Authors:  Andrea Lisco; Arshi Munawwar; Andrea Introini; Christophe Vanpouille; Elisa Saba; Xingmin Feng; Jean-Charles Grivel; Sarman Singh; Leonid Margolis
Journal:  J Infect Dis       Date:  2011-11-22       Impact factor: 5.226

Review 4.  Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence.

Authors:  Connie Celum; Jared M Baeten
Journal:  Curr Opin Infect Dis       Date:  2012-02       Impact factor: 4.915

Review 5.  Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?

Authors:  Christopher B Hurt; Joseph J Eron; Myron S Cohen
Journal:  Clin Infect Dis       Date:  2011-10-05       Impact factor: 9.079

Review 6.  HIV treatment as prevention and HPTN 052.

Authors:  Myron S Cohen; Marybeth McCauley; Theresa R Gamble
Journal:  Curr Opin HIV AIDS       Date:  2012-03       Impact factor: 4.283

7.  Antiretroviral prophylaxis: a defining moment in HIV control.

Authors:  Salim S Abdool Karim; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2011-07-21       Impact factor: 79.321

8.  Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.

Authors:  L A Lagenaur; B E Sanders-Beer; B Brichacek; R Pal; X Liu; Y Liu; R Yu; D Venzon; P P Lee; D H Hamer
Journal:  Mucosal Immunol       Date:  2011-07-06       Impact factor: 7.313

9.  A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.

Authors:  Jill L Schwartz; Wes Rountree; Angela D M Kashuba; Vivian Brache; Mitchell D Creinin; Alfred Poindexter; Brian P Kearney
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

10.  Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action.

Authors:  Raina N Fichorova; Hidemi S Yamamoto; Mary L Delaney; Andrew B Onderdonk; Gustavo F Doncel
Journal:  MBio       Date:  2011-10-25       Impact factor: 7.867
View more
  13 in total

1.  Semen enhances HIV infectivity and impairs the antiviral efficacy of microbicides.

Authors:  Onofrio Zirafi; Kyeong-Ae Kim; Nadia R Roan; Silvia F Kluge; Janis A Müller; Shibo Jiang; Benjamin Mayer; Warner C Greene; Frank Kirchhoff; Jan Münch
Journal:  Sci Transl Med       Date:  2014-11-12       Impact factor: 17.956

2.  Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Authors:  Randi B Gombos; Dror Kolodkin-Gal; Leila Eslamizar; Joshua O Owuor; Emanuele Mazzola; Ana M Gonzalez; Birgit Korioth-Schmitz; Rebecca S Gelman; David C Montefiori; Barton F Haynes; Joern E Schmitz
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

3.  Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1.

Authors:  Mark Contarino; Arangassery R Bastian; Ramalingam Venkat Kalyana Sundaram; Karyn McFadden; Caitlin Duffy; Vamshi Gangupomu; Michelle Baker; Cameron Abrams; Irwin Chaiken
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

4.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

5.  A new antiviral: chimeric 3TC-AZT phosphonate efficiently inhibits HIV-1 in human tissues ex vivo.

Authors:  Christophe Vanpouille; Anastasia Khandazhinskaya; Inna Karpenko; Sonia Zicari; Victor Barreto-de-Souza; Svetlana Frolova; Leonid Margolis; Sergey Kochetkov
Journal:  Antiviral Res       Date:  2014-07-07       Impact factor: 5.970

6.  Enhanced activity of carbosilane dendrimers against HIV when combined with reverse transcriptase inhibitor drugs: searching for more potent microbicides.

Authors:  Enrique Vacas-Córdoba; Marta Galán; Francisco J de la Mata; Rafael Gómez; Marjorie Pion; M Ángeles Muñoz-Fernández
Journal:  Int J Nanomedicine       Date:  2014-07-29

7.  Seminal plasma induces inflammation and enhances HIV-1 replication in human cervical tissue explants.

Authors:  Andrea Introini; Stéphanie Boström; Frideborg Bradley; Anna Gibbs; Axel Glaessgen; Annelie Tjernlund; Kristina Broliden
Journal:  PLoS Pathog       Date:  2017-05-19       Impact factor: 6.823

8.  Vaginal Lactobacillus Inhibits HIV-1 Replication in Human Tissues Ex Vivo.

Authors:  Rogers A Ñahui Palomino; Sonia Zicari; Christophe Vanpouille; Beatrice Vitali; Leonid Margolis
Journal:  Front Microbiol       Date:  2017-05-19       Impact factor: 5.640

9.  Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action.

Authors:  Axel Hollmann; Pedro M Matos; Marcelo T Augusto; Miguel A R B Castanho; Nuno C Santos
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

10.  Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen.

Authors:  Rafael Ceña-Diez; Pilar García-Broncano; Francisco Javier de la Mata; Rafael Gómez; M Ángeles Muñoz-Fernández
Journal:  Int J Nanomedicine       Date:  2016-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.